Human Antibody Transgenic Mice (BA-huMab)® + Phage Display Tech Platform

• Our BA-huMab® platform features the following advantages: Contains 30 human antibody κ light chain variable region genes, and 110 human antibody heavy chain variable region genes (IgM&IgG1); Directly generate human antibodies without need for humanization, which significantly accelerates antibody discovery process and decreases immunogenicity risk; Elicit an immune response quickly and produce a high antibody tier after immunization
• Our Phage display technology platform features the following advantages: efficient animal immunity technology, mature phage library construction technology, high-throughput and diverse phage based panning strategies, diverse evaluation capabilities for antibodies or antibody fragments

Bispecific T-cell Engager Technology Platform

• High affinity with tumor target antigen by bivalent binding to achieve better drug efficacy
• Low affinity with T cells by monovalent binding to lower toxicity
• Reduces CD3 antibody binding affinity which significantly reduces the risk of CRS

ADC Technology Platform

• Design, synthesis and screening potential ADC linker-payload
• Identification of potential internalized antibodies
• Diverse antibody conjugation technologies
• Evaluation of ADC in vitro and in vivo
• Process development and quality analysis for ADC products

Cell Therapy Technology Platform